Cosmo Pharmaceuticals NV
SIX:COPN

Watchlist Manager
Cosmo Pharmaceuticals NV Logo
Cosmo Pharmaceuticals NV
SIX:COPN
Watchlist
Price: 65 CHF Market Closed
Market Cap: 1B CHF
Have any thoughts about
Cosmo Pharmaceuticals NV?
Write Note

Cosmo Pharmaceuticals NV
Selling, General & Administrative

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cosmo Pharmaceuticals NV
Selling, General & Administrative Peer Comparison

Comparables:
PRGO
JAZZ
AVDL
G
GHRS
OVB

Competitive Selling, General & Administrative Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
Cosmo Pharmaceuticals NV
SIX:COPN
Selling, General & Administrative
-€34.3m
CAGR 3-Years
-25%
CAGR 5-Years
4%
CAGR 10-Years
-13%
Perrigo Company PLC
NYSE:PRGO
Selling, General & Administrative
-$1.2B
CAGR 3-Years
-2%
CAGR 5-Years
0%
CAGR 10-Years
-6%
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Selling, General & Administrative
-$1.4B
CAGR 3-Years
-4%
CAGR 5-Years
-15%
CAGR 10-Years
-14%
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Selling, General & Administrative
-$176.5m
CAGR 3-Years
-59%
CAGR 5-Years
-22%
CAGR 10-Years
-27%
G
GH Research PLC
NASDAQ:GHRS
Selling, General & Administrative
-$11.1m
CAGR 3-Years
-366%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ovoca Bio PLC
LSE:OVB
Selling, General & Administrative
-€1.2m
CAGR 3-Years
35%
CAGR 5-Years
16%
CAGR 10-Years
4%

See Also

What is Cosmo Pharmaceuticals NV's Selling, General & Administrative?
Selling, General & Administrative
-34.3m EUR

Based on the financial report for Jun 30, 2024, Cosmo Pharmaceuticals NV's Selling, General & Administrative amounts to -34.3m EUR.

What is Cosmo Pharmaceuticals NV's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-13%

Over the last year, the Selling, General & Administrative growth was -71%. The average annual Selling, General & Administrative growth rates for Cosmo Pharmaceuticals NV have been -25% over the past three years , 4% over the past five years , and -13% over the past ten years .

Back to Top